Infliximab for corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis

A retrospective study in six UK centers investigated outcomes of infliximab for corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis among patients with stage III or IV cancer. Fewer than half of the patients achieved corticosteroid-free clinical remission at twelve weeks after infliximab initiation. The cancer outcomes were better in patients with infliximab-resistant enterocolitis than in patients with infliximab-responsive enterocolitis.